According to a report by Vaporvoice, Pastel Cartel, the manufacturer of Esco Bars, has filed a lawsuit in the federal district court of western Texas in the United States.
According to court records, this dispute arose from the US Food and Drug Administration's (FDA) rejection of Esco Bars' tobacco products' pre-market application (PMTA).
In the lawsuit, Pastel Cartel accuses the FDA of refusing its PMTA due to technical reasons and behaving negligently and carelessly.
A temporary injunction has been implemented to suspend the RTA directive until the case is resolved. The ruling states that the RTA violated the Administrative Procedure Act (APA) and the due process clause of the Fifth Amendment of the US Constitution. The final decision revokes the RTA directive and returns the PMTA case to the FDA for further review.
According to a statement from the FDA, earlier the manufacturer of Esco Bars products and the distributor of Breeze products, Breeze Smoke, LLC, have also received warning letters for manufacturing, distributing, and/or importing unauthorized tobacco products in the United States.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
